MedTrace Logo

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

NCT05987345 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-07-22

No results posted yet for this study

Summary

The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field(PEF) treatment of metastatic non-small cell lung cancer(NSCLC) patients with acquired resistance to anti programmed cell death protein 1(PD-1) monoclonal antibody therapy.

The main questions it aims to answer are:

* Safety of PEF treatment of metastatic NSCLC patients.
* Control of ablated and other targeted lesions.
* Local and peripheral immunoregulation effect. PEF energy will be delivered to preselected lesions of participants, then anti PD-1 will be routinely administrated if no adverse event(AE)/serious adverse event(SAE) which need medical intervention occurs.

Conditions

Interventions

DEVICE

PEF

PEF device treated in the trial.

DRUG

Anti-PD-1 monoclonal antibody

Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.

Sponsors & Collaborators

  • Energenx Medical LTD.

    lead INDUSTRY

Principal Investigators

  • Shiyue Li, MD · The first Affiliated Hospital of Guanzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05987345 on ClinicalTrials.gov